DrugDashboards

Ondansetron

Ondansetron Hydrochloride · ONDANSETRON HYDROCHLORIDE 2 mg/mL · Injection, Solution · Intramuscular; Intravenous · Eugia US LLC

NDC 55150-0126-20 · 1 VIAL, MULTI-DOSE in 1 CARTON / 20 mL in 1 VIAL, MULTI-DOSE · ANDA · View full market →

The short version

Just 3 companies supply this market — thin enough that a single exit would be felt immediately. The price has jumped 180% in a year, to $0.3226 per unit — sharp rises like this often mean supply is already tightening. One of its named manufacturing plants, Eugia Pharma Specialities Limited, failed FDA inspectionwithin the last two years — the agency’s most serious outcome. Historically, drugs in this position went on to a new shortage within 90 days about 0.5% of the time — roughly 3× the typical drug (0.1%).

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

$0$0.2$0.4Jul 2013Sep 2020$0.3226
11 price points · per · last surveyed Invalid DateSource: CMS NADAC

Estimated fill cost

WAC per package, as filed
$5.00
Reported to Texas DSHS · 2025 annual filing · Eugia Us Llc

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicaid spend (2025)

$22
112 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

90-day shortage risk (model v2)

0.5%chance of a new FDA shortage posting for ondansetron hydrochloride (injectable) in the next 90 days

sterile injectable · OAI inspection at a producing facility (24 months) · sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is 3× that.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA202599
TE code
Approval date
Dec 21, 2012
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Ondansetron Hydrochloride (Injection, Solution)

LabelerStrengthFirst seenLast seen
Eugia US LLCONDANSETRON HYDROCHLORIDE 2 mg/mLJul 15, 2026Sep 3, 2026
Fresenius Kabi USA, LLCONDANSETRON HYDROCHLORIDE 4 mg/2mLJul 15, 2026Sep 3, 2026
Sagent PharmaceuticalsONDANSETRON HYDROCHLORIDE 2 mg/mLJul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Ondansetron — NDC 55150-0126-20," retrieved September 3, 2026, https://drugdashboards.com/drug/55150012620.

Free to cite with attribution — see how the data is put together.